Aeolus Pharmaceuticals, Inc. (AOLS) Receives Multi-year Award to Develop Treatment against Nerve Agent Exposure
Aeolus Pharmaceuticals, Inc., a biotechnology company developing a novel platform of compounds to treat radiation and chemical exposure, as well as oncology indications, today announced that NIH CounterACT has awarded a $735,951 contract to Manisha Patel, Ph.D., at the University of Colorado Anschutz Medical Campus. The funding is to support the development of AEOL 10150, Aeolus’ broad-spectrum catalytic antioxidant, as a medical countermeasure (MCM) against nerve agents. The grant was awarded with primary objectives in mind, including the evaluation of the neuroprotective efficacy of AEOL 10150 against pilocarpine (an organic compound of plant origin)-induced neurotoxicity in rat models; exposure to…